Aurobindo Pharma (NSE:AUROPHARMA) Long-Term Capital Lease Obligation : ₹2,525 Mil (As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Aurobindo Pharma Long-Term Capital Lease Obligation?

Aurobindo Pharma's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹2,525 Mil.

Aurobindo Pharma's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 (₹3,217 Mil) to Dec. 2023 (₹0 Mil) but then increased from Dec. 2023 (₹0 Mil) to Mar. 2024 (₹2,525 Mil).

Aurobindo Pharma's annual Long-Term Capital Lease Obligation increased from Mar. 2022 (₹3,186 Mil) to Mar. 2023 (₹3,215 Mil) but then declined from Mar. 2023 (₹3,215 Mil) to Mar. 2024 (₹2,525 Mil).

Aurobindo Pharma Long-Term Capital Lease Obligation Historical Data

The historical data trend for Aurobindo Pharma's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurobindo Pharma Long-Term Capital Lease Obligation Chart

Aurobindo Pharma Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

2,644.10

2,661.90

3,186.10

3,215.30

2,525.30

Aurobindo Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															3,215.30	-	3,216.90	-	2,525.30

Aurobindo Pharma (NSE:AUROPHARMA) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Aurobindo Pharma Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Aurobindo Pharma's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Aurobindo Pharma (NSE:AUROPHARMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aurobindo Pharma Ltd (NSE:AUROPHARMA) » Definitions » Long-Term Capital Lease Obligation

Traded in Other Exchanges

524804:India

Address

Plot No. 1, Survey No. 83/1, Galaxy, Floors: 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500 032

Website

https://www.aurobindo.com

Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. The company's product portfolio spans a variety of therapeutic areas. The vast majority of the company's sales are generated in the United States, followed by Europe. Most of Aurobindo's sales are derived from its formulations business, with the rest stemming from its active pharmaceutical ingredient operations. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Aurobindo Pharma (NSE:AUROPHARMA) Headlines

No Headlines